Results 91 to 100 of about 519,368 (313)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Time for quantitative clinical pharmacology : a proposal for a pharmacometrics curriculum

, 2007
A formal training program in pharmacometrics is essential to train clinical pharmacology scientists. A proposal is made for a pharmacometrics curriculum. The curriculum has components at the undergraduate, graduate and postgraduate levels.
Karlsson, Mats O.,, Holford, N
core   +1 more source

Optimising antidepressant therapy in pregnancy: a perspective on therapeutic drug monitoring and model-informed precision dosing

Frontiers in Pharmacology
Depression during pregnancy is common worldwide, with higher prevalences in low-income countries compared to high-income countries. Yet, current antidepressant dosing strategies in pregnant patients rarely account for the substantial pharmacokinetic ...
Sílvia M. Illamola, Kathleen M. Job, Angela K. Birnbaum, Angela K. Birnbaum, Angela K. Birnbaum, Angela K. Birnbaum, Maged M. Costantine, Catherine M. Sherwin, Catherine M. Sherwin, Catherine M. Sherwin, Catherine M. Sherwin, Catherine M. Sherwin   +11 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Clinical medication review: one step beyond: Computer rules of personal goals?

, 2019
In this ageing society, older persons are using more and more medications for chronic diseases. During a clinical medication review, the community pharmacist evaluate all the medication use together with the patient in a personal conversation.
Verdoorn, Marguerita Alexandra, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology   +2 more
core  

The specialty clinical pharmacology needs to be examined separately to guarantee a sufficient level of knowledge in medical students

, 2013
PurposeIn medical schools small specialties like clinical pharmacology may be integrated in courses covering larger specialties and examined concomitantly.
Wallerstedt, Susanna Maria,, Wallerstedt, Sven, Wallerstedt, Sven,, Wallerstedt, Susanna Maria, Wallerstedt, Mattias P., Wallerstedt, Mattias P.,   +5 more
core   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Intravenous-to-oral switch in anticancer chemotherapy : focus on taxanes and gemcitabine

, 2011
Most anticancer chemotherapeutic drugs are given intravenously. However, there is a growing interest in developing anticancer drugs for oral application.
Koolen, S.L.W., Clinical Pharmacology, Sub Clinical Pharmacology, NKI   +3 more
core  

Clinical Pharmacology Packages of FDA-Approved Biologic License Applications in Oncology from 2015 to 2025

Drugs and Drug Candidates
The landscape of oncologic therapies has undergone large changes since the introduction of monoclonal antibody (mAb) based immunotherapies in the late 1990s and early 2000s.
Kate Gallinero, Hunter Daws, Amanda Singh, Sanela Bilic   +3 more
doaj   +1 more source

Establishing an assay to evaluate d‐amino acid oxidase enzyme kinetics and inhibition using WST‐8 redox dye

FEBS Open Bio, EarlyView.
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake, Yuki Enoki, Yuka Nakazawa, Kazuaki Taguchi, Kazuaki Matsumoto   +4 more
wiley   +1 more source